
Pharmacally
CARDAMYST
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in CARDAMYST
Clinical TrialsMilestone Reports 66.7% PSVT Conversion With CARDAMYST After AblationMilestone Pharmaceuticals reported Phase 3 RAPID subgroup findings showing that CARDAMYST (etripamil) nasal spray converted recurrent paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm within 30 minutes in four…Fact-Checked
Clinical TrialsMilestone Opens Real-World Chapter for CARDAMYST With RESET-PSVTMilestone Pharmaceuticals unveiled RESET-PSVT, a planned Phase 4 observational registry designed to study real-world use, treatment patterns, and patient-reported outcomes of CARDAMYST nasal spray in adults with paroxysmal…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.